Literature DB >> 26076562

Noninvasive Markers of Improvement of Liver Steatosis Achieved by Weight Reduction in Patients with Nonalcoholic Fatty Liver Disease.

I Copaci, Ioana Lupescu, Elena Caceaune, Grethi Chiriac, G Ismail.   

Abstract

UNLABELLED: Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance and metabolic syndrome, which are linked to obesity. The aim of the study was to assess if weight reduction through 12 months of lifestyle intervention and exercise would lead to improvement of steatosis.
METHODS: In a prospective observational study 86 overweight subjects (51 men, 35 women) with steatosis were recruited, after excluding other etiologies. Patients were assigned a caloric goal and a daily fat goal. Physical activity focused on moderate-intensity activities. Blood samples (biochemistry, HOMA-IR, cytokine levels, steatotest) were collected at entry and months 6 and 12. All subjects underwent abdominal CT scan before commencement and after 12 months to assess visceral and subcutaneous adipose tissue (VAT/SAT) area.
RESULTS: After 12 months baseline descriptive characteristics (weight, BMI, waist circumference) decreased significantly. Biochemical parameters that decreased significantly were: GGT (40.0 ± 18.0 vs 31.1 ± 13; p = 0.01), ALT (58.5 ± 23.5 vs 32.7 ± 14.8; p = 0.001), cholesterol (236.4 ± 54.8 vs 204.8 ? 91; p = 0.05), LDL (160.1 ± 47.4 vs 125.3 ± 40; p = 0.05) and HOMA-R (4.86 ± 0.63 vs 3 ± 0.41; p = 0.018). Steatotest improved significantly (0.68 ± 0.16 vs 0.38 ± 0.14; p = 0.02). Modification of adipocytokines was significant for leptin (p = 0.018) and adiponectin (p = 0.003). Factors associated with regression of steatosis were weight, BMI, ALT, waist circumference, GGT, HOMA, leptin, VAT and steatotest. Multivariate logistic regression showed the following factors related to improved steatosis: BMI < 25 kg/m2, ALT < 42 U/L, leptin < 10.5 ng/ml and adiponectin > 8.4 μg/ml.
CONCLUSIONS: Overweight persons who achieve significant reductions in body weight through 12 months of physical activity and low caloric diet can decrease liver fat, VAT and SAT. Even in those with minimal weight loss ALT levels, steatosis, adipokines and cardiovascular risk factors improved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26076562     DOI: 10.1515/rjim-2015-0008

Source DB:  PubMed          Journal:  Rom J Intern Med        ISSN: 1220-4749


  6 in total

Review 1.  Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents.

Authors:  Hiroyasu Sakai; Yohei Shirakami; Masahito Shimizu
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 2.  The adipokines in the pathogenesis and treatment of nonalcoholic fatty liver disease.

Authors:  C Boutari; K Tziomalos; V G Athyros
Journal:  Hippokratia       Date:  2016 Oct-Dec       Impact factor: 0.471

3.  Arnebia euchroma ointment can reduce abdominal fat thickness and abdominal circumference of overweight women: A randomized controlled study.

Authors:  Mansour Siavash; Mohsen Naseri; Mojgan Rahimi
Journal:  J Res Med Sci       Date:  2016-08-01       Impact factor: 1.852

4.  Association between Non-Alcoholic Fatty Liver Disease and Mediterranean Lifestyle: A Systematic Review.

Authors:  Catalina M Mascaró; Cristina Bouzas; Josep A Tur
Journal:  Nutrients       Date:  2021-12-23       Impact factor: 5.717

5.  Association between Physical Activity and Non-Alcoholic Fatty Liver Disease in Adults with Metabolic Syndrome: The FLIPAN Study.

Authors:  Catalina M Mascaró; Cristina Bouzas; Sofia Montemayor; Miguel Casares; Cristina Gómez; Lucía Ugarriza; Pere-Antoni Borràs; José Alfredo Martínez; Josep A Tur
Journal:  Nutrients       Date:  2022-03-03       Impact factor: 5.717

6.  Long-lived hypopituitary Ames dwarf mice are resistant to the detrimental effects of high-fat diet on metabolic function and energy expenditure.

Authors:  Cristal M Hill; Yimin Fang; Johanna G Miquet; Liou Y Sun; Michal M Masternak; Andrzej Bartke
Journal:  Aging Cell       Date:  2016-03-17       Impact factor: 9.304

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.